Fr. 47.50

Edaravone Nanoparticles - Surface Response Methodology

English · Paperback / Softback

Shipping usually within 2 to 3 weeks (title will be printed to order)

Description

Read more

Objective of the present study is to prepare edaravone nanoparticle by using 3 level factorial deign using design expect 9 software. The software produced 17 formulations with varying concentration of EC, PVA and Tween-80 with a fixed dose of edaravone (5 mg). The drug and polymer compatibility study was done by FTIR spectroscopy. All the 17 formulations morphology was spherical in shape and the zeta potential in the rage of -12.7 mV to -28.5 mV. The particle size and entrapment efficiency was the main independent variable in formula optimization. The in-vitro dissolution of all the formulations were followed initial burst release followed by sustained release more than 12 hours. Based on the factorial design studies, we optimized formulation of edaravone nanoparticle.

About the author










Dr.Varatharajan Rajavel has been completed M.Pharm in Industrial Pharmacy, Annamalai University, India and PhD in Pharmacology, University of Malaya, Kuala Lumpur, Malaysia. Presently working as a Associate Professor in Faculty of Pharmacy, Asian Institute of Medicine and Technology University (AIMST), Kedah, Malaysia.

Product details

Authors Jaya Raja Kumar Kalaimani, Varatharajan Rajavel, Vijayan Venugopal
Publisher LAP Lambert Academic Publishing
 
Languages English
Product format Paperback / Softback
Released 28.09.2017
 
EAN 9783659851834
ISBN 978-3-659-85183-4
No. of pages 84
Dimensions 150 mm x 220 mm x 5 mm
Weight 144 g
Subject Natural sciences, medicine, IT, technology > Medicine > Pharmacy

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.